LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR to adjourn its Special Meeting of Stockholders in connection with the Alcon merger agreement (the "Special Meeting†). As a result, the Special Meeting, which was scheduled for December 19, 2025 at 8:30 a.m. Pacific Time, has been adjourned to January 6, 2026 ...

Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised Deal CHARLOTTE, N.C., Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement reiterating its intention to vote AGAINST the Company's proposed sale to Alcon Inc. ("Alcon") (NYSE: ALC) and expressing its disappoi ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following open letter to STAAR stockholders: Dear STAAR Surgical Stockholders: The Special Meeting of Stockholders to vote on the amended agreement with Alcon Inc. (SIX/NYSE: ALC) is just days away. How you vote at the Special Meeting will greatly influence the value of your shares. Yo. ...

® LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICLâ"¢) for vision correction, today reported that independent industry analysts have recognized the value provided to STAAR stockholders by the Company's amended merger agreement with Alcon (SIX/NYSE: ALC) and the merits of the Alcon transaction. The Alcon merger agreement, as revised on December 9, 2025, provides that STAAR stockholders wil ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) ("STAAR†), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICLâ"¢) for vision correction, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS†) has issued a new report and revised its recommendation with respect to STAAR's merger with Alcon. ISS is now recommending that all STAAR stockholders vote "FOR†STAAR's amended merger agree. ...

Core Viewpoint - BofA Securities has downgraded Alcon Inc. from Buy to Underperform and reduced its price target from $100 to $75 due to a negative outlook influenced by market softness, increased competition, and multiple guidance cuts affecting sentiment [1] Group 1: Market Conditions - The downgrade reflects a year characterized by market softness and heightened competition, which have negatively impacted Alcon's performance [1] - Analysts believe that consensus forecasts for improving confidence into 2026 are overly optimistic, expecting a sharp rebound and market share gains despite limited visibility [2] Group 2: Financial Estimates - BofA's fiscal 2026 and 2027 EPS estimates are 4% and 7% below consensus, indicating a cautious outlook [2] - The firm has cut its fiscal 2026 EPS by 8% and adjusted valuation multiples based on higher WACC assumptions and adverse market conditions [3] Group 3: Valuation Metrics - Despite a 20% valuation pullback from 2024 highs, Alcon's forward P/E ratio remains around 25x, which is considered elevated given the expected EPS CAGR of less than 10% from 2025 to 2027 [3]

Alcon, the Swiss eye-care specialist, got its first bearish mark from analysts since August after Bank of America double downgraded the stock https://t.co/UT38037zN1 ...

Core Viewpoint - Alcon is positioned for growth through strategic acquisitions, particularly the increased offer for Staar Surgical, which is expected to enhance its market presence in the eyecare sector [2][4]. Company Overview - Alcon is a leading Swiss eyecare company known for its innovative products and services in the healthcare sector, competing with major players in the eyecare and medical technology industries [1]. - The company's market capitalization is approximately $39.41 billion, indicating its significant presence in the healthcare industry [4]. Recent Developments - Alcon has initiated a new bid to acquire Staar Surgical at $30.75 per share, valuing the company at $1.6 billion, as part of its growth strategy [2]. - An amended merger agreement with Staar Surgical has been announced, marking a significant step in their collaboration [4]. Stock Performance - The current stock price for Alcon is $79.69, reflecting an increase of $1.02, or 1.30% [3]. - Over the past year, Alcon's stock has experienced volatility, with a high of $99.20 and a low of $71.55, indicating investor interest and market reactions to strategic decisions [3]. - Today's trading volume for Alcon is 975,777 shares, suggesting active investor engagement [5].

Core Viewpoint - Yunqi Capital Limited, holding a 5.1% stake in STAAR Surgical Company, has expressed strong opposition to Alcon Inc.'s revised acquisition offer of $30.75 per share, emphasizing that the sale process has been mishandled and does not maximize shareholder value [2][5][4]. Group 1: Acquisition Details - Alcon agreed to acquire STAAR Surgical for a total equity value of approximately $1.5 billion, which was later amended to $30.75 per share, raising the total equity value to approximately $1.6 billion [3]. - The revised purchase price represents an additional approximately $150 million in equity value for STAAR's stock [3]. Group 2: Shareholder Concerns - Broadwood Partners, owning a 30.2% stake in STAAR, criticized the sale process, stating that the new price is still roughly half of what Alcon offered in 2024, despite STAAR's projections remaining unchanged [4]. - Yunqi Capital believes it is not the right time to sell the company and argues that the sale process has been structured to favor Alcon, lacking transparency and failing to attract competitive bidders [5][6]. Group 3: Process Issues - The 30-day go-shop period was deemed too short for a credible market check for a global medical device company, with provisions that discouraged alternative buyers [6]. - STAAR reportedly contacted 21 parties, but Yunqi Capital claims the pool of potential buyers is significantly larger, indicating that the process may have deterred additional bidders [7]. Group 4: Market Performance - STAAR Surgical shares were down 5.65% at $23.95 at the time of publication, reflecting market concerns regarding the acquisition and the company's future prospects [8].

Group 1 - STAAR Surgical Company (STAA) received an acquisition offer from Alcon Inc. (ALC) in August for $28 per share, representing over a 50% premium to the prior share price [1] - The acquisition offer indicates a significant interest in STAAR Surgical by Alcon, suggesting potential growth opportunities in the ophthalmic device market [1] Group 2 - The article highlights the author's experience in analyzing undercovered companies, particularly in technology, software, electronics, and energy transition sectors [1] - The author emphasizes the importance of identifying asymmetric investment opportunities to achieve market-beating returns [1]